Home > Insider Trading > Filing (0000939767-25-000076)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
939767	Exelixis Inc.	EXEL	Biological Products, (No Disgnostic Substances) (2836)	043257395

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1682735	C. Amy Peterson	1851 Harbor Bay Parkway Alameda CA 94502	Evp Prod Dev & Med Aff & Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2025-05-15	8,303	$44.65	498,169	No	4	F	Direct
Common Stock	Acquisiton	2025-05-16	40,000	$21.75	538,169	No	4	M	Direct
Common Stock	Disposition	2025-05-16	72,776	$45.47	465,393	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option (right to buy)	Disposition	2025-05-16	40,000	$0.00	40,000	$21.75

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
120,000	2024-08-24	2030-08-23	No	4	M	Direct

Footnotes

Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded February 23, 2024.
Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $45.08 to $46.44. Reporting Person undertakes to provide Exelixis, Inc., any securityholder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth infootnote 3 to this Form 4.
The option, representing the right to purchase a total of 160,000 shares of Common Stock, 40,000 shares became exercisable on August 24, 2024 and the remainder will become fully exercisable on August 24, 2027.